An evidence-based meta-analysis of vascular endothelial growth factor inhibition in pediatric retinal diseases: Part 1. retinopathy of prematurity

Journal of Pediatric Ophthalmology and Strabismus

Volumn 49, Issue 6, 2012, Pages 332-340

  Mititelu, Mihai ^a   Chaudhary, Khurram M ^a   Lieberman, Ronni M ^b  

^a Department of Ophthalmology ^*  (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN;

CILIARY DISK; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HUMAN; LASER COAGULATION; META ANALYSIS; MONOTHERAPY; PEDIATRICS; RETINA DISEASE; RETROLENTAL FIBROPLASIA; REVIEW; TREATMENT OUTCOME; VITRECTOMY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; HUMANS; INFANT; INTRAVITREAL INJECTIONS; LASER COAGULATION; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY;

EID: 84872593517     PISSN: 01913913     EISSN: 19382405     Source Type: Journal    
DOI: 10.3928/01913913-20120821-03     Document Type: Review

References (59)

1. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003;8:469-473.
2. Saugstad OD. Oxygen and retinopathy of prematurity. J Perinatol. 2006;26:46-50.
3. Tasman W. Retinopathy of prematurity: do we still have a problem. Arch Ophthalmol. 2011;129:1083-1086.
4. Raizada S, Kandari JA, Sabti KA. Will the BEAT-ROP study results really beat ROP. Invest Ophthalmol Vis Sci. 2011;52:9288- 9289.
5. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial for cryotherapy of prematurity: three-month outcome. Arch Ophthalmol. 1990;108:195-204.
6. Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indication for the treatment of retinopathy of prematurity: results of Early Treatment for ROP randomized trial. Arch Ophthalmol. 2003;121:1684-1696.
7. Axer-Siegel R, Snir M, Cotlear D, et al. Diode laser treatment of posterior retinopathy of prematurity. Br J Ophthalmol. 2000;84:1383-1386.
8. Choi MY, Park IK, Yu YS. Long term refractive outcome in eyes of preterm infants with and without retinopathy of prematurity: comparison of keratometric value, axial length, anterior chamber depth, and lens thickness. Br J Ophthalmol. 2000;84:138-143.
9. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Effi cacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603-615.
10. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci. 2008;49:522-527.
11. Pieramici DJ, Avery RL. Ranibizumab: treatment in patients with neovascular age-related macular degeneration. Expert Opin Biol Ther. 2006;6:1237-1245.
12. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
13. Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F. A systematic review on the effect of bevacizumab in exudative agerelated macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009;247:1-11.
14. Nicholson BP, Schachat AP. A review of clinical trials of anti- VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:915-930.
15. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
16. Youn JY, Wang T, Cai H. An ezrin/calpain/PI3K/AMPK/ eNOSs1179 signaling cascade mediating VEGF-dependent endothelial nitric oxide production. Circ Res. 2008;104:50-59.
17. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87:77- 88.
18. Smith LE. Through the eyes of a child: understanding retinopathy through ROP. Invest Ophthalmol Vis Sci. 2008;49:5177-5182.
19. Wykoff CC, Houston SK, Berrocal AM. Anti-vascular endothelial growth factor agents for pediatric retinal diseases. Int Ophthalmol Clin. 2011;51:185-199.
20. Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet. Bevacizumab therapy for retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. Epub ahead of print December 30, 2011.
21. Micieli JA, Surkont M, Smith AF. A systematic analysis of the off-label use of bevacizumab for severe retinopathy of prematurity. Am J Ophthalmol. 2009;148:536-542.
22. Schünemann HJ, Oxman AD, Vist GE Jr, et al. Interpreting results and drawing conclusions. In: Higgins J, Green S. eds. Cochrane Handbook for Systematic Reviews of Interventions. Cichester: Wiley; 2008:391-32.
23. Hoang QV, Kiernan DF, Chau FY, Shapiro MJ, Blair MP. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment. Arch Ophthalmol. 2010;128:1080-1081.
24. Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL. Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS. 2010;14:6-10.
25. Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010;248:1257-1262.
26. Spandau U, Tomic Z, Ewald U, Larsson E, Akerblom H, Holmstrom G. Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol. Epub ahead of print January 23, 2012.
27. Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multi-center study in Taiwan. Ophthalmology. 2011;118:176-183.
28. Avery RL. Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both. J AAPOS. 2012;16:2-4.
29. Arevalo JF, Garcia-Amaris RA. Intravitreal bevacizumab for diabetic retinopathy. Curr Diabetes Rev. 2009;5:39-46.
30. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;3:257-261.
31. Hard AL, Hellstrom A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Pediatrica. 2011;100:1523-1527.
32. Anantharaman G, Pawar S, Vyas JP, Gopalakrishnan M. Bilateral regression of choroidal neovascularization associated with pathologic myopia following unilateral intravitreal bevacizumab injection. World Journal of Retina and Vitreous. 2011;1:23-26.
33. Ziemssen F, Zhu Q, Peters S, et al. Intensifi ed monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary fi ndings of a pilot study. Int Ophthalmol. 2009;29:213-224.
34. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelial-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010;94:1215-1218.
35. Qian J, Lu Q, Tao Y, et al. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina. 2011;31:161-168.
36. Ma Y, Zhang Y, Zhao T, Jiang YR. Vascular endothelial growth factor in plasma and vitreous fl uid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab. Am J Ophthalmol. 2012;153:307-313.
37. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897-1908.
38. Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol. 2007;22:201-204.
39. Lim SL, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents: should ophthalmologists be concerned. Am J Ophthalmol. 2011;152:329-331.
40. Sato T, Wada K, Arahori H, et al. Serum concentrations of bevacizumab (Avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012;153:327-333.
41. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000;106:1311-1319.
42. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF- 2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med. 2002;8:702-710.
43. Avery RL. Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: promise and concern. J AAPOS. 2009;13:320-331.
44. Lutty GA, McLeod DS, Bhutton I, Weigand SJ. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci. 2011;52:4039-4047.
45. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10:133-140.
46. Das A, McGuire PG. Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. Prog Retin Eye Res. 2003;22:721-748.
47. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
48. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy in zone I or posterior zone II. Retina. 2008;28:831-838.
49. Mintz-Hittner HA, Best, LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009;21:182-187.
50. Jonas JB, Schmidbauer M. Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol. 2009;87:571-572.
51. Dorta P, Kychental A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin). Retina. 2010;30:S24-S31.
52. Sato Y, Berkowitz BA, Wilson CA, de Juan E Jr. Blood-retinal barrier breakdown caused by diode vs. argon laser endophotocoagulation. Arch Ophthalmol. 1992;110:277-281.
53. Jang SY, Choi KS, Lee SJ. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J AAPOS. 2010;14:457-459.
54. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2008;246:1061-1063.
55. Kychental A, Dorta P. Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity. Retina. 2010;30:S32-S36.
56. Nazari H, Modarres M, Parvaresh MM, Falavarjani KG. Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2010;248:1713-1718.
57. Tsilou, E, Zhou M, Gahl W, Sieving PC, Chan C-C. Ophthalmic manifestations and histopathology of infantile nephropathic cystinosis: report of a case and review of the literature. Surv Ophthalmol. 2007;52:97-105.
58. Gahl WA, Kuehl EM, Iwata F, Lindblad A, Kaiser-Kupfer MI. Corneal crystals in nephropathic cystinosis: natural history and treatment with cysteamine eyedrops. Mol Genet Metab. 2000;71:100-120.
59. Norris J, Pilling R, Matthews B, Simmons I. Non-contact anterior segment OCT for corneal crystals in cystinosis. J Pediatr Ophthalmol Strabismus. 2009;46:128.